US › Healthcare

Cardiol Therapeutics Inc Class A (CRDL)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$1.36+3.82%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-10.8M
Profit YoY
-30.9%
EPS
$-0.05
EPS estimate
$-0.08

EPS came in at -0.05 against a street estimate of -0.08 — a beat of 37.5%.

Key statistics

Market cap
$151.0M
Forward P/E
0.0
P/B
8.49
Book value
$0.15
EPS (TTM)
$-0.28
52-week high
$1.71
52-week low
$0.88
50-day MA
$1.13
200-day MA
$1.12
Beta
0.47

Analyst view

Analysts rate Cardiol Therapeutics Inc Class A a buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $7.37.

Shareholding

Insiders
2.38%
Institutions
24.70%

Largest institutional holders

FundStake
Mmcap International Inc. Spc13.32%
Tejara Capital Ltd4.45%
Ikarian Capital, LLC2.36%
Citadel Advisors Llc0.71%
BOOTHBAY FUND MANAGEMENT, LLC0.69%
Two Sigma Investments LLC0.46%
INTEGRITY ALLIANCE, LLC.0.40%
The Goldman Sachs Group Inc0.29%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Cardiol Therapeutics Inc Class A — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.